BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1385 related articles for article (PubMed ID: 29971397)

  • 1. Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months: The HPV FOCAL Randomized Clinical Trial.
    Ogilvie GS; van Niekerk D; Krajden M; Smith LW; Cook D; Gondara L; Ceballos K; Quinlan D; Lee M; Martin RE; Gentile L; Peacock S; Stuart GCE; Franco EL; Coldman AJ
    JAMA; 2018 Jul; 320(1):43-52. PubMed ID: 29971397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT.
    Gilham C; Sargent A; Kitchener HC; Peto J
    Health Technol Assess; 2019 Jun; 23(28):1-44. PubMed ID: 31219027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25-69 years living in Australia.
    Canfell K; Saville M; Caruana M; Gebski V; Darlington-Brown J; Brotherton J; Heley S; Castle PE
    BMJ Open; 2018 Jan; 8(1):e016700. PubMed ID: 29374658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial.
    Canfell K; Caruana M; Gebski V; Darlington-Brown J; Heley S; Brotherton J; Gertig D; Jennett CJ; Farnsworth A; Tan J; Wrede CD; Castle PE; Saville M
    PLoS Med; 2017 Sep; 14(9):e1002388. PubMed ID: 28926579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary cervical cancer screening with an HPV mRNA test: a prospective cohort study.
    Sørbye SW; Fismen S; Gutteberg TJ; Mortensen ES; Skjeldestad FE
    BMJ Open; 2016 Aug; 6(8):e011981. PubMed ID: 27515759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
    Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
    Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis.
    Sherman ME; Lorincz AT; Scott DR; Wacholder S; Castle PE; Glass AG; Mielzynska-Lohnas I; Rush BB; Schiffman M
    J Natl Cancer Inst; 2003 Jan; 95(1):46-52. PubMed ID: 12509400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance of standardised colposcopy to detect cervical precancer and cancer for triage of women testing positive for human papillomavirus: results from the ESTAMPA multicentric screening study.
    Valls J; Baena A; Venegas G; Celis M; González M; Sosa C; Santin JL; Ortega M; Soilán A; Turcios E; Figueroa J; Rodríguez de la Peña M; Figueredo A; Beracochea AV; Pérez N; Martínez-Better J; Lora O; Jiménez JY; Giménez D; Fleider L; Salgado Y; Martínez S; Bellido-Fuentes Y; Flores B; Tatti S; Villagra V; Cruz-Valdez A; Terán C; Sánchez GI; Rodríguez G; Picconi MA; Ferrera A; Mendoza L; Calderón A; Murillo R; Wiesner C; Broutet N; Luciani S; Pérez C; Darragh TM; Jerónimo J; Herrero R; Almonte M;
    Lancet Glob Health; 2023 Mar; 11(3):e350-e360. PubMed ID: 36796982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection Rate of High-Grade Cervical Neoplasia and Cost-Effectiveness of High-Risk Human Papillomavirus Genotyping with Reflex Liquid-based Cytology in Cervical Cancer Screening.
    Tay SK; Lin LE; Goh RC
    Ann Acad Med Singap; 2017 Jul; 46(7):267-273. PubMed ID: 28821890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long term duration of protective effect for HPV negative women: follow-up of primary HPV screening randomised controlled trial.
    Elfström KM; Smelov V; Johansson AL; Eklund C; Nauclér P; Arnheim-Dahlström L; Dillner J
    BMJ; 2014 Jan; 348():g130. PubMed ID: 24435414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice.
    Katki HA; Kinney WK; Fetterman B; Lorey T; Poitras NE; Cheung L; Demuth F; Schiffman M; Wacholder S; Castle PE
    Lancet Oncol; 2011 Jul; 12(7):663-72. PubMed ID: 21684207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ARTISTIC: a randomised trial of human papillomavirus (HPV) testing in primary cervical screening.
    Kitchener HC; Almonte M; Gilham C; Dowie R; Stoykova B; Sargent A; Roberts C; Desai M; Peto J;
    Health Technol Assess; 2009 Nov; 13(51):1-150, iii-iv. PubMed ID: 19891902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary HPV testing with cytology versus cytology alone in cervical screening-A prospective randomized controlled trial with two rounds of screening in a Chinese population.
    Chan KKL; Liu SS; Wei N; Ngu SF; Chu MMY; Tse KY; Lau LSK; Cheung ANY; Ngan HYS
    Int J Cancer; 2020 Aug; 147(4):1152-1162. PubMed ID: 31922265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triaging HPV-positive women with normal cytology by p16/Ki-67 dual-stained cytology testing: baseline and longitudinal data.
    Uijterwaal MH; Polman NJ; Witte BI; van Kemenade FJ; Rijkaart D; Berkhof J; Balfoort-van der Meij GA; Ridder R; Snijders PJ; Meijer CJ
    Int J Cancer; 2015 May; 136(10):2361-8. PubMed ID: 25345358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CITRUS, cervical cancer screening trial by randomization of HPV testing intervention for upcoming screening: Design, methods and baseline data of 18,471 women.
    Morisada T; Teramoto K; Takano H; Sakamoto I; Nishio H; Iwata T; Hashi A; Katoh R; Okamoto A; Sasaki H; Nakatani E; Teramukai S; Aoki D
    Cancer Epidemiol; 2017 Oct; 50(Pt A):60-67. PubMed ID: 28818742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of type-specific human papillomavirus infections on the detection of cervical precancer and cancer: A population-based study of opportunistic cervical screening in the United States.
    Wheeler CM; Hunt WC; Cuzick J; Langsfeld E; Robertson M; Castle PE;
    Int J Cancer; 2014 Aug; 135(3):624-34. PubMed ID: 24226935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human papillomavirus test with cytology triage in organized screening for cervical cancer.
    Veijalainen O; Kares S; Kujala P; Tirkkonen M; Vuento R; Kholová I; Luukkaala T; Osuala V; Mäenpää J
    Acta Obstet Gynecol Scand; 2016 Nov; 95(11):1220-1227. PubMed ID: 27591407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial.
    Kitchener HC; Almonte M; Thomson C; Wheeler P; Sargent A; Stoykova B; Gilham C; Baysson H; Roberts C; Dowie R; Desai M; Mather J; Bailey A; Turner A; Moss S; Peto J
    Lancet Oncol; 2009 Jul; 10(7):672-82. PubMed ID: 19540162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pooled analysis of a self-sampling HPV DNA Test as a cervical cancer primary screening method.
    Zhao FH; Lewkowitz AK; Chen F; Lin MJ; Hu SY; Zhang X; Pan QJ; Ma JF; Niyazi M; Li CQ; Li SM; Smith JS; Belinson JL; Qiao YL; Castle PE
    J Natl Cancer Inst; 2012 Feb; 104(3):178-88. PubMed ID: 22271765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 70.